J Bacteriol Virol.
2015 Dec;45(4):382-388. 10.4167/jbv.2015.45.4.382.
Current Advances in the Development of Vaccines and Therapeutic Agents Against MERS-coV
- Affiliations
-
- 1Department of Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Korea. innks@khu.ac.kr
- KMID: 2168723
- DOI: http://doi.org/10.4167/jbv.2015.45.4.382
Abstract
- Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by the betacoronavirus (MERS-CoV). Since the isolation and identification of MERS-CoV in 2012, cases have been spread to neighboring nations in Arabian Peninsula area and Europe. The recent outbreak of MERS in Korea confirmed that MERS-CoV is capable of causing epidemics through person-to-person transmission. Despite of its high mortality, there is no available effective vaccine and therapeutic agent partly due to its short history. So far, ribavirin and interferon therapy has been failed to prove its efficacy in human patients. Thus, there is an urgent need for the effective countermeasures such as vaccines and therapeutics. In the current review, recent advances in the development of vaccines and therapeutic antibodies have been discussed.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19
- Lessons Learned from SARS-CoV and MERS-CoV: Preparation for SARS-CoV-2 induced COVID-19
- Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control
- Antiviral Treatment Guidelines for Middle East Respiratory Syndrome
- Epidemiology, Virology, and Clinical Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; Coronavirus Disease-19)
